Keros Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
KROS$9.33+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| THREE MONTHS ENDED MARCH 31, | ||
|---|---|---|
| 2026 | 2025 | |
| REVENUE: | ||
| Service and other revenue | $367 | $15,891 |
| License revenue | — | 195,355 |
| Total revenue | 367 | 211,246 |
| OPERATING EXPENSES: | ||
| Research and development | (16,097) | (48,709) |
| General and administrative | (10,147) | (10,497) |
| Total operating expenses | (26,244) | (59,206) |
| INCOME (LOSS) FROM OPERATIONS | (25,877) | 152,040 |
| OTHER INCOME (EXPENSE), NET | ||
| Dividend income | 2,335 | 6,792 |
| Other expense, net | (166) | (338) |
| Total other income, net | 2,169 | 6,454 |
| Income (loss) before income taxes | (23,708) | 158,494 |
| Income tax provision | — | (10,043) |
| Net income (loss) | $(23,708) | $148,451 |
| Net income (loss) attributable to common stockholders — basic and diluted (Note 9) | $(23,708) | $148,451 |
| Weighted-average shares of common stock outstanding — basic | 19,629,906 | 40,559,355 |
| Weighted-average shares of common stock outstanding — diluted | 19,629,906 | 41,021,325 |
| Net income (loss) per share of common stock — basic | $(1.21) | $3.66 |
| Net income (loss) per share of common stock — diluted | $(1.21) | $3.62 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.